SCHEMBL20579

SCHEMBL20579

Nc1nc2nc[nH]c2c(=O)n1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.50
PNP P00491 2/20 0.49
PDPK1 O15530 1/20 0.44
GDA Q9Y2T3 1/20 0.44
ALDH1A1 P00352 1/20 0.42
CDK2 P24941 2/20 0.42
MAP3K5 Q99683 1/20 0.39
PI4KA P42356 2/20 0.38
PI4K2B Q8TCG2 2/20 0.38
PI4K2A Q9BTU6 2/20 0.38
PI4KB Q9UBF8 2/20 0.38
LMNA P02545 2/20 0.38
XDH P47989 2/20 0.38
DRD3 P35462 1/20 0.38
LRRK2 Q5S007 1/20 0.38
ATAD2 Q6PL18 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
PIK3CD O00329 1/20 0.37
ALPL P05186 1/20 0.37
ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41788 0.81 PNP (0.50) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL2983851 0.79 PNP (0.49) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL2051365 0.79 PNP (0.49) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL27975255 0.79 PNP (0.49) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL852108 0.79 PNP (0.49) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL1843777 0.79 PNP (0.49) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL20867 0.79 ATAD2 (0.53) DPP4PNPPDPK1GDALMNA
SCHEMBL8886040 0.79 PNP (0.49) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL6821773 0.79 PNP (0.45) DPP4PNPPDPK1GDAALDH1A1
SCHEMBL27602647 0.79 ATAD2 (0.49) DPP4PNPPDPK1GDALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630867-B2 Devices for CRISPR effector system based diagnostics THE BROAD INSTITUTE, INC. (US) 2026-05-19 US disclosed
US-20250243471-A1 PROGRAMMABLE PATTERN RECOGNITION COMPOSITIONS BROAD INST INC (US) 2025-07-31 US disclosed
US-20250223580-A1 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS THE BROAD INSTITUTE, INC. 2025-07-10 US disclosed
US-20250129355-A1 PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS NATIONAL INSTITUTES OF HEALTH 2025-04-24 US disclosed
US-20250075268-A1 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-03-06 US disclosed
US-12203145-B2 CRISPR effector system based diagnostics for virus detection THE BROAD INSTITUTE, INC. (US) 2025-01-21 US disclosed
EP-4119663-B1 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS BROAD INST INC (US) 2024-11-27 EP disclosed
CN-111448311-B Diagnostic system based on multiple effector CRISPR 博德研究所 2024-11-19 CN disclosed
CN-111108220-B Diagnostic based on CRISPR effect system for virus detection 博德研究所 2024-11-19 CN disclosed
US-20240352454-A1 MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-10-24 US disclosed
EP-1546164-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG Life Sciences Ltd. (KR) 2005-06-29 EP disclosed
US-20040127454-A1 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases RESPROTECT GMBH (DE) 2004-07-01 US disclosed
WO-2004029064-A1 (+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF LG LIFE SCIENCES LTD. (KR) 2004-04-08 WO disclosed
EP-1334109-A2 IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES Santaris Pharma A/S (DK) 2003-08-13 EP disclosed
US-20020086998-A1 Synthesis of purine locked nucleic acid analogues SANTARIS PHARMA A/S (DK) 2002-07-04 US disclosed
WO-2002028875-A2 IMPROVED SYNTHESIS OF PURINE LOCKED NUCLEIC ACID ANALOGUES CUREON A/S (DK) 2002-04-11 WO disclosed
WO-2002024323-A2 HIGH DENSITY MOLECULAR ARRAYS ON POROUS SURFACES PICOLITER INC. (US) 2002-03-28 WO disclosed
EP-0824536-B1 ANTIMALARIAL ORGANOMETALLIC IRON COMPLEXES UNIV LILLE SCIENCES TECH (FR) 2001-08-22 EP disclosed
EP-0338168-A1 Phosphonoalkylpurine derivatives MERRELL DOW PHARMACEUTICALS INC. (US) 1989-10-25 EP disclosed
US-4508898-A Antiviral triazine compounds SYNTEX (U.S.A.) INC. 1985-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086998-A1 Synthesis of purine locked nucleic acid analogues RNGTT, PNP, UNG DPP4 312/4885PNP 2/4885PDPK1 1460/4885
US-20040127454-A1 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases PNP, TYMP, ENTPD5 DPP4 469/4885PNP 1/4885PDPK1 2377/4885
US-12630867-B2 Devices for CRISPR effector system based diagnostics ZFR, MTREX, ADAR DPP4 797/4885PNP 2592/4885PDPK1 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.